On May 16, 2018 CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform, reported that preliminary clinical results from PROCLAIM-072, an ongoing Phase 1/2 trial evaluating CX-072, a Probody therapeutic targeting PD-L1, will be presented at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) (Press release, CytomX Therapeutics, MAY 16, 2018, View Source [SID1234527068]). The conference will take place from June 1-5 in Chicago, Illinois.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Two posters will detail initial results from two ongoing dose escalation arms of the PROCLAIM-CX-072 trial as monotherapy and in combination with Yervoy (ipilimumab) in patients with advanced unresectable solid tumors.
"Our goal at CytomX is to reinvent therapeutic antibodies for the treatment of cancer and these first-in-human data represent a key milestone for the Probody platform," said Sean McCarthy, D.Phil., president and chief executive officer of CytomX Therapeutics. "We look forward to expounding on our initial findings, published today in abstract form, at ASCO (Free ASCO Whitepaper). The preliminary data in these abstracts are encouraging as we are observing initial signs of antitumor activity for both CX-072 monotherapy and the ipilimumab combination, in this difficult-to-treat, late-stage patient population for whom approved PD-agents are not available. Furthermore, these data suggest that CX-072 is well tolerated and shows an encouraging, emerging safety profile as a monotherapy and in combination with ipilimumab. Taken together, our preliminary findings are consistent with the Probody hypothesis and align with our vision of transforming lives with safer, more effective therapies."
CytomX’s ASCO (Free ASCO Whitepaper) poster presentations will include longer follow-up periods in both the monotherapy and combination arms, as well as data from additional patients treated in combination with ipilimumab and will reflect a data cutoff approximately five months after the abstract data cutoff. Additional data from the PROCLAIM-072 trial is expected during the second half of 2018 and in 2019.
Abstract 3071/Poster #285 – Preliminary Results of the First-In-Human, Dose-Finding PROCLAIM-072 Trial of the PD-L1 Probody Therapeutic CX-072 as Monotherapy in Patients with Advanced Solid Tumors
Presenter: Karen A. Autio, M.D., MSc., Memorial Sloan Kettering Cancer Center
Session: Developmental Therapeutics—Immunotherapy
Date/Time: Monday, June 4, 8:00 – 11:30 a.m.
Location: Hall A
Abstract 3072/Poster #286 – Preliminary Interim Results of the First-In-Human, Dose-Finding PROCLAIM-072 Trial of the PD-L1 Probody Therapeutic CX-072 in Combination with Ipilimumab in Patients with Advanced Solid Tumors
Presenter: Rachel E. Sanborn, M.D., Earle A. Chiles Research Institute, Providence Cancer Center
Session: Developmental Therapeutics—Immunotherapy
Date/Time: Monday, June 4, 8:00 – 11:30 a.m.
Location: Hall A
Abstract Book – Preliminary Single-Dose Clinical Pharmacokinetics of an Anti–PD-L1 Probody Therapeutic (Pb-Tx) in Cancer Patients
Pharmacokinetic data published in the conference abstract book suggests that CX-072 is behaving as designed in circulation and that CX-072 circulates predominately in the intact, masked form with low or no binding to the target in the periphery.
CytomX’s posters will be available online under the Events and Presentations section of the CytomX website at the time of presentation at www.CytomX.com.
CytomX will be hosting a conference call and webcast on Monday, June 4, 2018 to discuss the ASCO (Free ASCO Whitepaper) poster presentations with specific event details to be announced closer to the start of the conference.
About PROCLAIM
PROCLAIM (Probody Clinical Assessment In Man) is an international umbrella program designed to evaluate CytomX Probody therapeutics. The first module is the PROCLAIM-072 clinical program, an open-label, dose-finding Phase 1/2 trial evaluating CX-072 as monotherapy and in combination with Yervoy (ipilimumab) or Zelboraf(vemurafenib) in patients with metastatic or locally advanced unresectable solid tumors or lymphomas. CytomX aims to achieve three goals as part of the PROCLAIM-072 clinical trial:
Tolerability: Demonstrate that CX-072 is well tolerated in patients, and potentially improves safety, particularly in the combination setting.
Anti-cancer activity: Demonstrate initial evidence of CX-072’s anti-cancer activity as monotherapy and in combination.
Translational program and Probody platform proof-of-concept: Explore mechanistic aspects of Probody activity in patients as observed in preclinical models.